Search
Relay Therapeutics Inc
RLAYAdd to Watchlist
18.650USD
+0.890+5.01%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
3.24BMarket Cap
LossP/E TTM
More Details of Relay Therapeutics Inc Company
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Relay Therapeutics Inc Info
Ticker SymbolRLAY
Company nameRelay Therapeutics Inc
IPO dateJul 16, 2020
CEOPatel (Sanjiv K)
Number of employees261
Security typeOrdinary Share
Fiscal year-endJul 16
Address60 Hampshire Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139
Phone16173708837
Websitehttps://relaytx.com/
Ticker SymbolRLAY
IPO dateJul 16, 2020
CEOPatel (Sanjiv K)
Company Executives of Relay Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
266.70K
-0.28%
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
229.91K
+22.16%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexis A. Borisy
Mr. Alexis A. Borisy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
266.70K
-0.28%
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
229.91K
+22.16%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
FAQs
Who are the top five shareholders of Relay Therapeutics Inc?
The top five shareholders of Relay Therapeutics Inc are: Dr. Mark Murcko, Ph.D.
How many institutions hold shares of Relay Therapeutics Inc (RLAY)?
As of 2026Q1, 474 institutions hold shares of Relay Therapeutics Inc, with a combined market value of approximately 194.30M, accounting for 101.48% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -3648091.00.